Compare Ascendis Pharma A/S (ASND) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lockheed Martin Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lockheed Martin Corporation trades at $526.13 (market cap $120.64B). The key difference: Lockheed Martin Corporation is far larger — about 6.8× Ascendis Pharma A/S's market cap, and Lockheed Martin Corporation pays a 2.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LMT | |
|---|---|---|
Market Cap | $17.74B | $120.64B |
Sector | Health | Industrials |
52-Week High | $277.18 | $676.70 |
52-Week Low | $163.32 | $410.74 |
Enterprise Value | $18.11B | $139.44B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lockheed Martin (LMT) trades at $523.22, up 0.96% on the day, with a bearish technical signal despite recent positive momentum. The company reported $75.05B in 2025 revenue but missed Q1 2026 EPS estimates. Strong analyst consensus favors a buy rating with a $627.50 price target, supported by a $3.45 dividend and robust defense contracts, including a recent $3.5B naval acquisition and European missile production deals.
Outlook remains positive due to elevated defense spending and a $186.4B backlog, though risks include execution challenges and geopolitical volatility. The stock presents value with a P/E of 25.34 and high ROE of 67.64%, but investors should monitor earnings consistency and debt levels, which have risen to 36.26% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
